147 related articles for article (PubMed ID: 36738305)
1. Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study.
Yagi K; Maruo A; Ishida S; Aizawa F; Ushio S; Sakaguchi S; Kajizono M; Niimura T; Goda M; Hamano H; Izawa-Ishizawa Y; Zamami Y; Ishizawa K
Clin Exp Med; 2023 Oct; 23(6):2799-2804. PubMed ID: 36738305
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells.
Ando-Matsuoka R; Yagi K; Takaoka M; Sakajiri Y; Shibata T; Sawada R; Maruo A; Miyata K; Aizawa F; Hamano H; Niimura T; Izawa-Ishizawa Y; Goda M; Sakaguchi S; Zamami Y; Yamanishi Y; Ishizawa K
Drug Dev Res; 2023 Feb; 84(1):75-83. PubMed ID: 36484282
[TBL] [Abstract][Full Text] [Related]
3. Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: A nationwide database study.
Tsujita K; Deguchi H; Uda A; Sugano K
J Cardiol; 2020 Jul; 76(1):51-57. PubMed ID: 32184027
[TBL] [Abstract][Full Text] [Related]
4. Comparative study: Vonoprazan and proton pump inhibitors in
Sakurai K; Suda H; Ido Y; Takeichi T; Okuda A; Hasuda K; Hattori M
World J Gastroenterol; 2017 Jan; 23(4):668-675. PubMed ID: 28216974
[TBL] [Abstract][Full Text] [Related]
5. Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect.
Yagi K; Mitstui M; Zamami Y; Niimura T; Izawa-Ishizawa Y; Goda M; Chuma M; Fukunaga K; Shibata T; Ishida S; Sakurada T; Okada N; Hamano H; Horinouchi Y; Ikeda Y; Yanagawa H; Ishizawa K
Cancer Med; 2021 Jan; 10(1):164-172. PubMed ID: 33231381
[TBL] [Abstract][Full Text] [Related]
6. Vonoprazan versus proton pump inhibitors for postendoscopic submucosal dissection bleeding in the stomach: a multicenter population-based comparative study.
Shiratori Y; Niikura R; Ishii N; Ikeya T; Honda T; Hasatani K; Yoshida N; Nishida T; Sumiyoshi T; Kiyotoki S; Arai M; Kawai T; Fukuda K
Gastrointest Endosc; 2022 Jan; 95(1):72-79.e3. PubMed ID: 34237329
[TBL] [Abstract][Full Text] [Related]
7. Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study.
Kojima Y; Takeuchi T; Sanomura M; Higashino K; Kojima K; Fukumoto K; Takata K; Sakamoto H; Sakaguchi M; Tominaga K; Higuchi K
Digestion; 2018; 97(1):70-75. PubMed ID: 29393198
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis.
Iwakiri K; Sakurai Y; Shiino M; Okamoto H; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Ashida K
Therap Adv Gastroenterol; 2017 Jun; 10(6):439-451. PubMed ID: 28567114
[TBL] [Abstract][Full Text] [Related]
9. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
[TBL] [Abstract][Full Text] [Related]
10. Vonoprazan poses no additional risk of developing Clostridioides difficile infection compared to proton pump inhibitors.
Saruta Y; Watanabe K; Tsuji T; Takahashi Y; Matsuzawa H; Yoshida T; Takahashi S; Shimodaira Y; Matsuhashi T; Iijima K
J Gastroenterol Hepatol; 2023 Jun; 38(6):940-947. PubMed ID: 36882162
[TBL] [Abstract][Full Text] [Related]
11. Potent Acid Suppression With Vonoprazan vs Proton Pump Inhibitors Does Not Have Higher Association With Clostridioides difficile Infection.
Watanabe K; Shimodaira Y; Takahashi S; Fukuda S; Koizumi S; Matsuhashi T; Iijima K
Am J Gastroenterol; 2021 Aug; 116(8):1632-1637. PubMed ID: 33989224
[TBL] [Abstract][Full Text] [Related]
12. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
Miwa H; Igarashi A; Teng L; Uda A; Deguchi H; Tango T
J Gastroenterol; 2019 Aug; 54(8):718-729. PubMed ID: 30919071
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of vonoprazan for management of post-endoscopic submucosal dissection ulcers compared with proton pump inhibitors: A meta-analysis.
Liu C; Feng BC; Zhang Y; Li LX; Zuo XL; Li YQ
J Dig Dis; 2019 Oct; 20(10):503-511. PubMed ID: 31414725
[TBL] [Abstract][Full Text] [Related]
14. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
[TBL] [Abstract][Full Text] [Related]
15. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
[TBL] [Abstract][Full Text] [Related]
16. Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan.
Sugawara K; Koizumi S; Horikawa Y; Mimori N; Tsuji T; Ishii H; Fujimori S; Onochi K; Watanabe H; Iijima K
J Gastroenterol; 2019 Nov; 54(11):963-971. PubMed ID: 31037448
[TBL] [Abstract][Full Text] [Related]
17. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Use of Vonoprazan and Proton Pump Inhibitors for the Treatment of Peptic Ulcers Resulting from Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis.
He HS; Li BY; Chen QT; Song CY; Shi J; Shi B
Med Sci Monit; 2019 Feb; 25():1169-1176. PubMed ID: 30755541
[TBL] [Abstract][Full Text] [Related]
19. Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: A systematic review with meta-analysis.
Kang H; Kim BJ; Choi G; Kim JG
Medicine (Baltimore); 2019 Jun; 98(24):e15860. PubMed ID: 31192917
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor.
Tack J; Vladimirov B; Horny I; Chong CF; Eisner J; Czerniak R; Takanami Y
Neurogastroenterol Motil; 2023 Jan; 35(1):e14468. PubMed ID: 36178335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]